NCT02674009View on ClinicalTrials.gov

Observational Study to Determine the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Locally Advanced Basal Cell Carcinoma (laBCC)

CompletedOBSERVATIONAL
Enrollment

67

Participants

Timeline

Start Date

September 17, 2015

Primary Completion Date

March 31, 2019

Study Completion Date

March 31, 2019

Conditions
Carcinoma, Basal Cell
Interventions
DRUG

Vismodegib

Participants with laBCC will receive a dosing of Vismodegib in accordance with local clinical practice and local labeling.

Trial Locations (1)

60590

Klinik Johann Wolfgang von Goethe Uni; Klinik für Dermatologie, Venerologie und Allergologie, Frankfurt

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02674009 - Observational Study to Determine the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Locally Advanced Basal Cell Carcinoma (laBCC) | Biotech Hunter | Biotech Hunter